Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07096349

Multidimensional Assessment of Chronic Pain in Severe Haemophilia A

Multidimensional Assessment of Chronic Pain in Severe Haemophilia A Treated With Monoclonal Antibodies: an Observational Study; an Ambispective Cohort Study

Status
Recruiting
Phase
Study type
Observational
Enrollment
109 (estimated)
Sponsor
Investigación en Hemofilia y Fisioterapia · Network
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

Introduction: Haemophilia is a congenital coagulopathy characterised by haemarthrosis, mainly in the knees, ankles and elbows. Prophylactic treatment is the most effective therapeutic option for preventing or minimising these bleeds. Bispecific monoclonal antibodies have been shown to be effective in reducing bleeding in patients with haemophilia. Objectives: To investigate the associations between chronic residual pain and pain catastrophising, perceived self-efficacy regarding the disease and treatment, and body image and perception of visible disability. Methods. Multicentre cross-sectional cohort studies. 109 patients with severe haemophilia A from different regions of Spain will be included in the study. The primary variable will be chronic residual pain and its functional interference (Brief Pain Inventory-Short Form). Secondary variables will be pain catastrophising (Pain Catastrophising Scale), perceived self-efficacy regarding the disease and treatment (Pain Self-Efficacy Questionnaire), and body image and perception of visible disability (Body Image Scale). Potential confounding variables will include sociodemographic variables (age and educational level), clinical variables (time on monoclonal antibody treatment and number of previous bleeds in the last 12 months) and anthropometric variables (body mass index). Expected results: It is expected that residual chronic pain will persist in patients with severe haemophilia A treated with monoclonal antibodies and that it will be associated with greater catastrophising, lower self-efficacy and poorer body image, modulating the experience of pain beyond bleeding control.

Conditions

Timeline

Start date
2025-07-30
Primary completion
2025-10-03
Completion
2025-10-26
First posted
2025-07-31
Last updated
2025-08-01

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT07096349. Inclusion in this directory is not an endorsement.